CO2021015462A2 - Antibodies and formulations of anti-cd38 - Google Patents

Antibodies and formulations of anti-cd38

Info

Publication number
CO2021015462A2
CO2021015462A2 CONC2021/0015462A CO2021015462A CO2021015462A2 CO 2021015462 A2 CO2021015462 A2 CO 2021015462A2 CO 2021015462 A CO2021015462 A CO 2021015462A CO 2021015462 A2 CO2021015462 A2 CO 2021015462A2
Authority
CO
Colombia
Prior art keywords
antibodies
formulations
methods
preparing
human
Prior art date
Application number
CONC2021/0015462A
Other languages
Spanish (es)
Inventor
Béatrice Cameron
Cendrine Lemoine
Blondel Marielle Chiron
Jacques Dumas
Alain Fournier
Jonathan Kingsbury
Brian Murray
Nathan Ostberg
Sanket Patke
Angela Virone-Oddos
Zichuan Zhang
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2021015462A2 publication Critical patent/CO2021015462A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en este documento anticuerpos que se unen específicamente a CD38 humana, formulaciones y formas de dosificación unitaria que comprenden los anticuerpos, métodos de preparación de los anticuerpos y métodos de uso de los anticuerpos.Provided herein are antibodies that specifically bind to human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies, and methods of using the antibodies.

CONC2021/0015462A 2019-04-23 2021-11-17 Antibodies and formulations of anti-cd38 CO2021015462A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US201962859699P 2019-06-10 2019-06-10
EP20305146 2020-02-17
EP20305145 2020-02-17
PCT/US2020/029531 WO2020219681A1 (en) 2019-04-23 2020-04-23 Anti-cd38 antibodies and formulations

Publications (1)

Publication Number Publication Date
CO2021015462A2 true CO2021015462A2 (en) 2021-12-10

Family

ID=70739160

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0015462A CO2021015462A2 (en) 2019-04-23 2021-11-17 Antibodies and formulations of anti-cd38

Country Status (14)

Country Link
EP (1) EP3958898A1 (en)
JP (1) JP2022529502A (en)
KR (1) KR20220003562A (en)
CN (1) CN114269375A (en)
AU (1) AU2020261039A1 (en)
BR (1) BR112021021060A2 (en)
CA (1) CA3137365A1 (en)
CO (1) CO2021015462A2 (en)
IL (1) IL287477A (en)
MA (1) MA55761A (en)
MX (1) MX2021012967A (en)
SG (1) SG11202111602YA (en)
TW (1) TW202104269A (en)
WO (1) WO2020219681A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023148A2 (en) 2004-07-10 2006-03-02 Fox Chase Cancer Center Genetically modified human natural killer cell lines
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EA034989B1 (en) * 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Polypeptide construct for use in treating cancer comprising attenuated alpha interferon
US10385135B2 (en) * 2015-11-03 2019-08-20 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108752475B (en) * 2018-06-14 2021-07-30 北京智仁美博生物科技有限公司 Anti-human CD38 antibodies and uses thereof

Also Published As

Publication number Publication date
EP3958898A1 (en) 2022-03-02
KR20220003562A (en) 2022-01-10
MA55761A (en) 2022-03-02
JP2022529502A (en) 2022-06-22
IL287477A (en) 2021-12-01
TW202104269A (en) 2021-02-01
WO2020219681A1 (en) 2020-10-29
SG11202111602YA (en) 2021-11-29
AU2020261039A1 (en) 2021-12-09
BR112021021060A2 (en) 2021-12-14
CN114269375A (en) 2022-04-01
MX2021012967A (en) 2022-01-18
CA3137365A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
CO2020016619A2 (en) Bispecific anti-pvrig / anti-tigit antibodies and methods of use
CL2017003261A1 (en) Factor xi antibodies and methods of use
CO2021001893A2 (en) Anti-gdf15 antibodies, compositions and methods of use
CL2017003023A1 (en) Anti-ctla-4 antibodies and methods of use thereof.
CO2018003477A2 (en) Anti-PD1 antibodies and methods of use
CL2017001736A1 (en) Anti-CD47 antibodies and use thereof.
CO2020012360A2 (en) Multispecific antibodies and their use
CO2017013351A2 (en) Cot modulators and methods of using them
PE20200617A1 (en) ANTI-CD39 ANTIBODIES, COMPOSITIONS INCLUDING ANTI-CD39 ANTIBODIES, AND METHODS OF USE OF ANTI-CD39 ANTIBODIES
ECSP21026339A (en) ANTI-HLA-G ANTIBODIES, COMPOSITIONS COMPRISING ANTI-HLA-G ANTIBODIES, AND METHODS OF USE OF ANTI-HLA-G ANTIBODIES
AR114789A1 (en) ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
UY36862A (en) ANTI-BODY CONJUGATES ANTI-DLL3-DRUG AND METHODS OF USE
DOP2018000272A (en) ANTI-EGFR AND DRUG ANTIBODIES
CL2018001722A1 (en) New anti-mfi2 antibodies and methods of use (divisional application 201700506)
CR20130313A (en) ANTI-CD38 ANTIBODIES
ECSP20063690A (en) ANTIBODIES
CO2021016834A2 (en) Cot modulators and methods of using them
NI201900034A (en) ANTIBODIES THAT BIND AND USE OF THE ZIKA VIRUS ENVELOPE PROTEIN
ECSP21021189A (en) PEDIATRIC DOSAGE FORMS OF VITAMIN D, METHODS OF PREPARATION AND USE
CO2022009510A2 (en) Compounds active against nuclear receptors
AR101486A1 (en) ANTIBODIES ANTI PROTEIN SIMILAR TO ANGIOPOYETINA 4 AND METHODS OF USE
AR101671A1 (en) ANTIBODIES ANTI PROTEIN SIMILAR TO ANGIOPOYETINA-4 (ANGPTL4) AND METHODS OF USE
CO2021015462A2 (en) Antibodies and formulations of anti-cd38
CL2021003228A1 (en) Tricyclic compounds and their use
ECSP20082970A (en) ANTI-SEZ6 DRUG AND ANTIBODY CONJUGATES AND METHODS OF USE